SCHEMBL6313465

SCHEMBL6313465

CSc1nc2ccccc2n1CC(C)O

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.55
HTT P42858 3/20 0.55
POLB P06746 2/20 0.55
LMNA P02545 4/20 0.53
TSHR P16473 1/20 0.51
ALDH1A1 P00352 3/20 0.50
KMT2A Q03164 3/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
MEN1 O00255 2/20 0.50
RECQL P46063 1/20 0.48
L3MBTL1 Q9Y468 2/20 0.47
AGER Q15109 1/20 0.46
APAF1 O14727 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6276823 1.00 MAPT (0.55) MAPTHTTPOLBLMNATSHR
SCHEMBL8360122 1.00 MAPT (0.55) MAPTHTTPOLBLMNATSHR
SCHEMBL6285172 0.87 ALDH1A1 (0.67) MAPTHTTPOLBLMNATSHR
SCHEMBL6280071 0.85 NPC1 (0.59) MAPTHTTPOLBLMNATSHR
SCHEMBL6281551 0.82 PTGDR2 (0.64) MAPTSMN1; SMN2CYP3A4CYP2C19NPSR1
SCHEMBL6279563 0.82 ALDH1A1 (0.51) MAPTHTTPOLBLMNATSHR
SCHEMBL3972391 0.81 MAPT (0.60) MAPTHTTPOLBLMNATSHR
SCHEMBL6277488 0.80 AR (0.56) MAPTPOLBKMT2AMEN1
SCHEMBL6282492 0.80 MEN1 (0.50) MAPTPOLBLMNATSHRALDH1A1
SCHEMBL6177373 0.80 SMN1; SMN2 (0.69) MAPTHTTPOLBLMNATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6875765-B2 Arylsulfonamide ethers, and methods of use thereof WARNER-LAMBERT COMPANY (US) 2005-04-05 US disclosed
US-20030096826-A1 Arylsulfonamide ethers, and methods of use thereof WARNER-LAMBERT COMPANY 2003-05-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030096826-A1 Arylsulfonamide ethers, and methods of use thereof CASP1, IRAK1, STS MAPT 268/4885HTT 677/4885POLB 4412/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.